drugset / Trial / NCT01001936
Study Evaluating SKI-606 in Subject With Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of oral SKI-606 (100, 200, 300 or 400 mg) administered on a daily schedule to subjects with advanced malignant solid tumors and to define a maximum tolerated dose (MTD) in this subject population. This study will also obtain preliminary information on the pharmacokinetics and antitumor activity of orally administered SKI-606 in subjects with advanced malignant solid tumors
Timeline
- Start
- 2006-02
- Primary completion
- 2008-12
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bosutinib | Small molecule | 100 mg | Oral |
| Subject | Bosutinib | Small molecule | 200 mg | Oral |
| Subject | Bosutinib | Small molecule | 300 mg | Oral |
| Subject | Bosutinib | Small molecule | 400 mg | Oral |